Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations

Elacestrant

Status: In Rekrutierung

Klinische Settings

Beteiligte

Identifier

Publikationen

Kontakt